A nationwide prospective survey on hepatitis C virus (HCV) infections among dialysis patients in The Netherlands was performed. Patients were recruited from 34 dialysis centers and were tested for antibodies and HCV RNA in 1995 and 1997. Seronegative serum samples were analyzed by reverse-transcriptase polymerase chain reaction in pools. HCV-RNApositive serum samples were genotyped and were partly sequenced. In the first and second rounds, 67 (2.9%) of 2281 and 76 (3.4%) of 2286 patients were HCV positive, respectively. Of 960 patients with paired serum samples, 35 were HCV positive in both rounds, and 9 HCVpositive cases were newly identified in the second round. The incidence of HCV infection was 0.5 per 100 dialysis years. Phylogenetic analysis revealed clustered sequences that indicated nosocomial transmission. Sixty percent of HCV infections, however, can be attributed to 4 interdependent risk factors (i.e., hemodialysis before 1992, kidney transplantation before 1994, and birth or dialysis in a foreign country). In conclusion, the prevalence of HCV infections in The Netherlands does not decline, and transmission within dialysis units continues. Adequate screening of HCV infections and strict enforcement of universal infection control practices are required.
The prevalence of hepatitis C virus (HCV) infections among dialysis patients varies markedly from country to country, ranging from 3% in northern Europe to 120% in southern Europe [1, 2] . Thus far, most studies reported data from a limited number of dialysis patients, often from a single center; however, the prevalence of HCV-infected patients also can vary considerably between centers in a single country [1, 3] . To assess the situation in dialysis patients in The Netherlands, a nationwide survey was performed, which revealed that the prevalence of HCV infection in dialysis patients was ∼3% in 1995 [1] .
Blood transfusion, kidney transplantation, and treatment within a dialysis unit are considered as the main risk factors for HCV infections in dialysis patients. At present, effective screening of blood and kidney donors for antibodies to HCV has considerably reduced the risk of transmission of HCV through blood and transplanted organs [4, 5] . Several studies, however, have shown that the prevalence and incidence of HCV infections remain high among dialysis patients, which may be explained by transmission within dialysis centers, probably because of inadequate adherence to infection control measures [6] [7] [8] .
Earlier studies also have shown that the diagnosis of HCV infection in dialysis patients by serological methods may not be sufficiently reliable, yielding false-negative results in ∼5%-10% of the HCV-infected dialysis patients [1, 9] . This is due to the impaired immune response of dialysis patients, which results in a prolonged seronegative window phase after infection. Therefore, molecular diagnostic methods, such as the reverse transcriptase (RT) polymerase chain reaction (PCR) offer useful complementary tools. The combination of serology and HCV-RNA detection is the most sensitive approach for diagnosis of HCV infections in dialysis patients [1, 9] .
Here we present the results of a nationwide prospective study on the epidemiology of HCV infections in hemodialysis patients in The Netherlands. This study comprised 2 separate sampling rounds and used serological, as well as molecular diagnostic, tools in a large number of patients. This approach permitted the estimation of the prevalence, as well as the incidence, of HCV infections in dialysis patients in The Netherlands. Phylogenetic analysis of HCV-positive serum samples was used to determine the relationship among individual isolates. Furthermore, the analysis of associated risk factors for recent HCV infections allowed for the development of an effective strategy to reduce the prevalence and incidence of HCV infections and to monitor the effect of more strictly enforced infection control measures, to prevent future HCV transmission among dialysis patients.
Materials and Methods
Dialysis centers and patients. In The Netherlands (with a population of ∼16 million), ∼4300 patients undergo chronic hemo-or peritoneal dialysis in 49 centers distributed over the country. In 1995, all 49 dialysis centers in The Netherlands were invited to participate in a nationwide study, of which 35 centers participated. During the study period, 2 centers merged and are considered as 1 center in the analysis of the data. Four centers that participated in the first round were not able to participate in the second round because of logistic reasons, such as shortage of staff or relocation of the center during the second sampling period.
Serum samples. In the first round, serum samples were collected from September 1995 through July 1996. The second round was performed from March 1997 through August 1998. Serum samples were prepared within 2 h after sampling, were frozen at Ϫ20ЊC, and were transported on dry ice. All serum samples were divided into 0.5-mL aliquots at a separate location to prevent contamination and unnecessary thawing and freezing. Aliquots were prepared before any diagnostic assays were performed.
Serology. All serum samples were tested by the INNO-test HCV AB III EIA (Innogenetics, Gent, Belgium) for the presence of antibodies to HCV. EIA-positive serum samples were examined by the INNO-line immunoassay (LIA) HCV AB III Update confirmation assay (Innogenetics), containing antigens from the core, NS3, NS4, and NS5 regions.
Molecular assays. Molecular screening for the presence of HCV RNA and genotypic analysis were performed as described elsewhere [1] . In brief, all anti-HCV-positive serum samples were tested individually for the presence of HCV RNA by RT-PCR, with primers aimed at the 5 untranslated region (UTR). To permit molecular screening of the large number of anti-HCV-negative serum samples, a pooling strategy was developed. Three to 5 anti-HCV-negative serum samples were pooled, and the mixture was tested for the presence of HCV RNA. In all assays, a low-level internal RNA control molecule was used to monitor the performance of the RT-PCR method. If this internal control was not detected, the assay was repeated, using a 5-fold higher amount of internal control RNA. If the internal control remained undetectable, the serum sample was considered to contain inhibitory substances, and no RT-PCR result could be provided.
For genotypic analysis the reverse hybridization line probe assay (INNO-line probe assay [LiPA] HCVII; Innogenetics) was used, which assesses type-specific sequence variation in the 5 UTR. For sequence analysis, part of the genome comprising the hypervariable region of the envelope protein encoding gene (E2; nucleotide positions 1439-1746) was amplified [7] . Sequences of the amplimers were determined by cycle sequencing (Perkin Elmer, Nieuwerkerk aan de IJssel, The Netherlands), using an ALF Express Electrophoresis Unit (Pharmacia, Leiden, The Netherlands). Phylogenetic analysis of a 263-bp sequence was performed using DNAMAN (Lynnon Biosoft, Vaudreuil, Quebec, Canada). Molecular distances were calculated using Jukes and Cantor parameters, and the results were graphically represented using the TREECON software (version 1.3) [10] .
Risk factor analysis. For each HCV-infected case that was newly identified in the second sampling round, one age-matched control patient was selected from the same center. For this casecontrol study, we used a structured questionnaire to obtain data from patients, medical files, dialysis nurses, and information present in the records of the dialysis centers. The study focused on the following items: country of birth, duration and history of dialysis, dialysis in foreign countries, number of renal transplants, operations, and blood transfusions. We separately assessed the duration of dialysis before 1992, because routine blood screening for HCV was introduced in The Netherlands in 1991-1992. We also determined the number of renal transplants before 1994, when routine screening for HCV of all kidney donors was introduced in the Eurotransplant region, which supplies postmortal kidneys to the Dutch transplant centers.
Statistical analysis. 
Results
First and second sampling rounds. Thirty-four dialysis centers participated in a nationwide prospective study on the prevalence and incidence of HCV infections. Taken together, ∼52% of the dialysis population in The Netherlands participated in the study. The diagnostic results are summarized in table 1. In the first round (serum samples obtained in [1995] [1996] , 2281 dialysis patients were sampled, of whom 473 (20.7%) were on peritoneal dialysis. Combining results from serology and RT- In the second round (serum samples obtained in 1997-1998), 2286 patients participated, of whom 449 (19.6%) were on peritoneal dialysis. Combining results from serology and RT-PCR, 76 (3.4%) patients were found to be HCV positive. Of these 76 patients, 74 (97.4%) were EIA positive and were confirmed by INNO-LIA. Fifty-nine (77.6%) of the 74 INNO-LIA-positive serum samples were HCV-RNA positive, 8 were HCV-RNA negative, and 7 showed inhibition of the RT-PCR. All seronegative serum samples were tested in 453 pools by RT-PCR, and 2 additional HCV-RNA-positive patients were identified. Two pools tested showed inhibition of RT-PCR, but testing of the separate serum samples revealed that they all were HCV-RNA negative.
HCV infections were not uniformly distributed among the participating centers, with a prevalence ranging from 0% to 11%. Only 2 (5.9%) of the 34 centers had no HCV-infected patients during both study periods.
Paired serum samples. Serum samples were obtained in both the first and the second rounds from 960 dialysis patients (42% of the total of each round). The average interval between these paired serum samples ranged from 1.02 to 2.61 years (average, 1.94 years). Of the 960 patients from whom paired serum samples were available, 35 were found HCV positive in the first round. HCV RNA was detected in 30 (85.7%) of these serum samples, and, in the second round, serum samples from these patients were also HCV-RNA positive. Thus, 30 paired serum samples were HCV-RNA positive in both rounds, and of these 3 (10%) were seronegative in the first round. During the follow-up period, 2 of these cases (patients 11 and 12; table 2) showed a seroconversion, whereas the other patient (patient 13; table 2) remained antibody negative during the entire study period of 20 months. None of the 30 patients who were HCV-RNA positive in the first round lost HCV RNA. Also, none of the 32 seropositive cases lost antibodies during follow-up.
Of the remaining 925 patients with paired serum samples that were negative during the first round, 9 patients from 6 different centers became HCV infected during the study period, with an average interval of 1.9 years (table 2) . Therefore, incidence of HCV infections in this study group was ∼0.5 per 100 dialysis years. Table 2 summarizes the data from the 9 novel HCV-positive cases, as well as 3 cases that were HCV-RNA positive but seronegative, in the first round. All diagnostic findings in these cases were confirmed by repeating the analysis on a separate aliquot of the serum samples. Patients 1-4 seroconverted during the follow-up period and were infected with HCV genotype 2b. All these patients were treated in the same dialysis center. Sequence analysis showed that the HCV isolates from these 4 patients were closely related to another genotype 2b isolate from a patient in the same center who was already found positive during the first round (figure 1, cluster 2b) [8] . Serum samples from patients 5-7 represent novel HCV infections from different centers. Patient 8 showed a confirmed seroconversion, but no HCV RNA was detected in serum samples from the first and second rounds. The seroconversion of patient 9 is based on the conversion of the LIA result from indeterminate to positive but remained HCV-RNA negative. Patients 10 and 11 were seronegative during the first round but contained HCV RNA, as detected by testing of seronegative pools. Serum samples from these patients, obtained during the second round, were found to be seropositive and contained HCV RNA of the corresponding genotype. Finally, patient 12 remained seronegative during the entire follow-up period but was consistently HCV-RNA positive with genotype 1b.
Genotypes. All paired HCV-RNA-positive serum samples ( ) showed unchanged genotypes in the first and second n p 30 rounds. In 2 patients, a mixed genotype 1a/1b infection was detected in serum samples from the first round, whereas only 1 of the 2 genotypes (1a in one serum sample and 1b in the other) could be identified in the second-round serum sample. In the second round, no patients with mixed infections were diagnosed. Overall, the distributions of HCV genotypes in the first and second rounds were similar, with genotypes 1a and 1b being the most prevalent.
Sequence analysis and phylogenetic analysis. HCV-RNApositive isolates from both rounds were used for further analysis. The 5 end of the E2 gene, comprising the hypervariable region (HVR-E2), was amplified by RT-PCR and directly sequenced. A total of 124 HVR-E2 sequences were used for phylogenetic analysis; the results are shown in figure 1 . From the first round, 62 sequences were obtained, including 54 from the centers also participating in the second round, as well as 8 sequences from centers that participated only in the first round. In the second round, 49 HVR-E2 sequences were obtained. Serum samples were obtained from 4 HCV-positive patients belonging to the genotype 2b cluster between the 2 rounds in 1996. Nine reference sequences were obtained from GenBank, representing different genotypes. In 14 HCV-RNA positive serum samples (4 from the first round and 10 from the second round), no PCR products could be obtained from the HVR-E2 region, despite the use of multiple primer sets.
All sequences contained a continuous open-reading frame, and a considerable fraction of the mutations was nonsynonymous (i.e., resulted in amino acid sequence mutations [synonymous, nonsynonymous substitution ratio, K s : ]). This is com-K p .66 a patible with the hypothesis of mutation selection, which is driven by antibody production against specific HVR-E2 epitopes [11] .
The phylogenetic tree represents the molecular distances among all HVR-E2 sequences. The different genotypes can be clearly distinguished, and the classification of each of the sequences was identical to the genotyping results of the LiPA, which is based on 5 UTR sequences.
Paired HVR-E2 sequences were obtained from 29 of the 30 patients who were HCV positive in both 1995 and 1997. In 1 serum sample from 1997, the HVR-E2 sequence could not be determined. The sequences within each pair were highly similar, as indicated by their consistent paired clustering in the tree and the limited length of their connecting branches. The average nucleotide sequence similarity among the 29 paired sequences was . The only exception is isolate AM62, where 94.1% ‫ע‬ 4.3% the molecular distance between the 1995 and 1997 sequences was much longer (only 81% similarity).
Clusters. Several clusters of HVR-E2 sequences were observed, indicating the existence of phylogenetically related isolates. Within such clusters, molecular distances are significantly smaller than the average distance between unrelated sequences (including published reference sequences).
The first cluster comprised 4 paired isolates of genotype 2a, obtained from patients in a single dialysis center. All patients were HCV-RNA positive in the first round and remained positive during follow-up. All the sequences determined from the 1995 and 1997 serum samples clustered together, which indicates a common source of infection ( figure 1, cluster 2a) . During follow-up, no additional related cases were observed.
The second cluster comprised 8 related HVR-E2 sequences (figure 1, cluster 2b) that were obtained from 6 patients in the same dialysis center as the genotype 2a cluster. This cluster was further analyzed, and characteristics of the implicated patients are shown in table 3. In 1995, only patient I was found to be infected with genotype 2b in this particular dialysis center. Subsequently, 4 patients (patients II-V) developed unexplained elevated alanine aminotransferase (ALT) levels and were also found to be infected with a genotype 2b strain. In addition, 2 additional patients (patients VI and VII) were found to be positive during the second round in 1997. Phylogenetic analysis showed that patients I-VI were all closely related, which suggests transmission, whereas patient VII was not related to this cluster ( figure  1 ). This finding was consistent with the fact that patient VII was already infected before entry into this dialysis center.
Sequences (genotype 1b) from patients AX72 and AX36, which were found to be HCV positive in 1997, were highly similar to those of patient AX56 from the same dialysis center ( figure 1, cluster A) . This strongly suggests that patients AX72 and AX36 have been infected from either patient AX56 or a common source. In 1995, patient AX56 was the only HCVpositive patient in this particular dialysis center, and, in 1997, only patients AX56, AX36, and AX72 were HCV positive.
Sequences from serum samples CJ26 (1997) and BC13 (1995) were closely related (cluster B). Further investigation revealed that centers CJ and BC had merged during the follow-up period and that serum samples CJ26 and BC13 had been obtained from the same patient.
Serum samples from patients AA15 and BE03 (figure 1, cluster C) also contained highly similar sequences but were different from patients treated in different centers in The Netherlands. Investigation of the medical history revealed that 1 patient (patient BE03) had undergone dialysis in Turkey and moved to The Netherlands in 1996. The other patient (patient AA15) was treated in the same Turkish dialysis center at the same time as patient BE03.
Sequences from patients AB13 (1995) and BN60 (1997) were highly similar ( figure 1, cluster D) . These serum samples were obtained from different dialysis centers. Further investigation, however, revealed that these serum samples were from the same patient, who had been transferred from center AB to center BN between 1995 and 1997.
The sequence from patient AA90, found positive in 1997, was highly similar to that of patient AA120, again from the same center ( figure 1, cluster E) . It is interesting that patient AA120 was persistently seronegative in 1995 and 1997 (table 2, patient 12). Moreover, these patients are from the same center (AA), where the genotype 2a and 2b clusters have been identified earlier, and underwent dialysis in the same unit of this center on the same days.
The sequence from patient AQ24 (1997) was similar to that from patient AQ21 in 1995 ( figure 1, cluster F) ; however, patient AQ21 did not participate in the second sampling round. In this particular center, 4 HCV-positive patients (3 with genotype 1a and 1 with 2a) who were all phylogenetically unrelated were found in 1995. On the basis of the phylogenetic tree, it can be concluded that patient AQ24 was infected from patient AQ21 or a common source. Risk investigations revealed that patient AQ24 seroconverted between 1995 and 1997 and had no other risk factors than hemodialysis. Sequences from patients CJ38 (1997) and AK04 (1995) were also similar ( figure 1, cluster G) . Centers CJ and AK were located in the same city, but relevant data concerning the dialysis history of both patients could not be obtained.
Case-control study and analysis risk factors. Comparison of the 41 newly identified HCV case patients with 41 age-and center-matched control patients showed the following: infected patients had been on dialysis for a longer duration (3.7 ‫ע‬ 0.8 vs.
years; ), had received more kidney trans-1.5 ‫ע‬ 0.4 P p .001 plants (
), and had been on dialysis in foreign countries P p .013 ( vs. weeks; ) than were their control 11 ‫ע‬ 5 0.5 ‫ע‬ 0.3 P p .029 patients. The length of peritoneal dialysis, the number of blood transfusions, and the number of operations did not differ significantly between case and control patients. Recovery of data on blood transfusions from the study group, however, was not sufficiently accurate to permit reliable statistical analysis.
As presented in table 4, significant odds ratios were found for hemodialysis before 1992, renal transplantation before 1994, foreign country of birth, and (holiday) dialysis in foreign countries. From the calculated attributable risk showed, it might be concluded that each of these 4 risk factors are responsible for 25%-40% of the HCV-infected patients in dialysis units. Loglinear model analysis, however, showed mutual dependence between hemodialysis before 1992 and both renal transplantation before 1994 ( ) and dialysis in foreign countries ( P ! .001 P p ). This last factor was related to foreign country of birth. .03 Therefore, it is more appropriate to look at the odds ratio for these 4 factors combined, which explains 62% of the newly identified HCV infections in Dutch dialysis centers. Odds ratios for peritoneal dialysis before 1992, operations before 1992 (more than the median of 1 operation), and blood transfusions (more than the median of 7 blood transfusions) failed to reach significance.
Evaluation of the medical history of all 41 newly identified HCV-infected dialysis patients showed that 3 different patient groups are responsible for the persistent burden of HCV in Dutch dialysis units. The first group ( ) included patients n p 14 with a documented recent infection (9 based on laboratory diagnosis from our study and 5 based on detailed serological data collected from the case-control study). The second, and largest, group ( ) included patients who had a (mostly n p 17 long-standing) history of dialysis or kidney transplantation before their first test of HCV. The third group ( ) included n p 10 patients who were already positive for HCV before the start of renal replacement therapy.
Discussion
The present study describes a nationwide prospective survey on the epidemiology of HCV infections in dialysis patients. Serological and molecular tools were used to analyze serum samples from all patients, comprising 150% of all dialysis patients in The Netherlands.
At present, all donor blood (since 1992) and kidney donors (since 1994) are screened for antibodies to HCV, to prevent transmission of the virus. Also, the use of erythropoietin has reduced the need for blood transfusion of dialysis patients, and there is a rapid turnover among dialysis patients ‫%02ע(‬ per year in The Netherlands) because of death or successful kidney transplantation. Therefore, one would expect a decrease in the prevalence of HCV infections among dialysis patients. However, at the beginning of the study in 1995-1996, 2.9% of the dialysis patients were infected, and, in the second sampling round in 1997-1998, the prevalence was 3.4%. Thus, the present study showed that the prevalence of HCV infections among dialysis patients in The Netherlands did not decline during the study period. Only 2 (5.9%) of the 34 participating centers had no HCV-infected patients during the entire study period, which indicates that HCV infections are a general problem. HCV-infected patients, however, were not uniformly distributed over the centers, and the prevalence ranged from 0% to 11%, which indicates that local and center-specific factors play an important role.
The seronegative window phase in dialysis patients may be relatively long. Therefore, it is difficult to assess the true prevalence and incidence of HCV infections among dialysis patients when only serology is used. The combination of serological and molecular methods allows for a more accurate estimation of both the prevalence and incidence of HCV infections. During the follow-up period of patients who were HCV negative during the first sampling round, 9 patients in 6 different centers showed a seroconversion and/or became HCV-RNA positive. Thus, the yearly incidence of HCV infection among dialysis patients in The Netherlands was estimated at ∼0.5 per 100 dialysis years.
During the first round, 5 patients were anti-HCV negative but had detectable HCV-RNA levels. Two of these patients were lost for follow up. Two patients (table 2) remained HCV-RNA positive and seroconverted during the follow-up period. One patient remained antibody negative for 11 year [12] . Because dialysis patients seem to have a prolonged anti-HCV-negative window phase, the number of seronegative, HCV-RNApositive patients will be related to the incidence of recently infected patients [9, 12, 13] . The diagnostic strategy, using HCV-RNA assays and pooling of anti-HCV-negative serum samples, was highly reliable and permitted identification of HCV infections at an early stage [1, 9, 12] . In addition, early detection of infected patients allowed for the application of interferon therapy during the first stages of infection. Recent studies suggest that early antiviral therapy of HCV might be more efficacious than treatment of chronic infections [14] . If early treatment is successful, these patients will not become chronically infected and will not be a potential source for transmission of HCV.
Serum samples that were HCV-RNA positive in both the first and second round all contained identical HCV genotypes. Sequence analysis of parts of the HCV genome permitted detailed phylogenetic studies and allowed for the effective tracing of nosocomial infections [8] . Sequences from patients who were HCV positive in 1995 and in 1997 were all clustered in pairs but were not completely identical. This finding is consistent with the postulated rapid evolution of the HVR-E2 sequences over time. Sequences from only a single patient (AM62) were more diverged than expected. This may be due to a high evolution rate in this patient. Earlier studies have already indicated that the evolution of the HVR-E2 may not be continuous in time but may depend on the immune activity of the host [11] . Alternatively, this patient may already have contained a population of substantially different HCV variants in 1995. Because sequences were determined without cloning, a shift in this population of variants, possibly caused by the host's immune response, may result in a significantly different consensus sequence.
Because of the relatively high evolution rate of the HVR, the relation among sequences can be recognized only if the time period between sampling moments is not too long. This limits the use of this genomic region for long-term epidemiological studies, for which other regions, such as E1 or NS5b, are more suitable. For short-term epidemiological studies, however, HVR-E2 sequences are highly informative, although direct sequencing does not allow for the analysis of the precise quasi-species composition of a complex HCV population in a patient. That a high percentage of the mutations results in amino acid changes is in agreement with earlier findings and is also consistent with the nature of the hypervariable region. Normally, protein-encoding genes show a much higher K s :K a value, which indicates conservation of the amino acid sequence. In contrast, the high degree of nonsynonymous mutations in the HVR of HCV results in frequent amino acid changes, yielding modified HVR protein epitopes. Such epitopes elicit specific humoral immune responses, which subsequently can provide selective pressure, causing continuous evolution of the quasi-species population in a patient. It is unknown whether the impaired immune response of dialysis patients is equally capable of such immune-mediated selection of HCV variants as in nondialysis patients.
All serum samples have been tested under code, and the fact that all sequences from the same patients clustered confirm the reliability of the study performance. A cluster of genotype 2a sequences already had been identified in 1995; however, additional transmissions were found by comparing sequences obtained in 1997 with those obtained in 1995. Sequences of HCV isolates from dialysis patients can be used to construct a database to monitor the quality of infection control in dialysis centers. HCV isolates from novel infections can be sequenced and compared with sequences in the database, to assess similarity to isolates observed earlier. Because the turnover of dialysis patients in each unit is high, because of death or kidney transplantation, the interval between screenings should not be too long. Also, in cases with unexplained raised serum levels of liver enzymes, HCV testing could be highly informative, as shown by analysis of the genotype 2b cluster. In fact, an HCV infection is nearly always heralded by a mild ALT increase during the incubation period before seroconversion.
More than half of the HCV infections have been acquired in the past, as indicated by the case-control study. More than 60% of the risk that Dutch dialysis patients will be infected with HCV can be attributed to the combination of 4 interdependent risk factors: hemodialysis before 1992, kidney transplants before 1994, birth in a foreign country, and (holiday) dialysis in a foreign country (most of them with a high prevalence of HCV). Hence, it not surprising that the precise moment of infection cannot be determined in 27 (65%) of the newly identified HCV-infected patients. We identified a recent infection in 14 patients, and phylogenetic analysis provided evidence for nosocomial transmission in most of these patients. These findings demonstrate that transmission within a dialysis unit may play an important role in the transmission of HCV. On the other hand, patients may also have acquired HCV through other routes of infection and may already be HCV infected at entry in the dialysis center. Therefore, novel patients should be screened upon entry, to monitor the influx of HCV-infected patients in each dialysis center.
Because the precise route of transmission remains unclear, there are no specific measurements that can be taken to prevent transmission of HCV in dialysis units. Some studies, however, have shown a significant reduction or even the elimination of transmission, after introducing strict universal precautions. In a prospective multicenter study in Belgium, it was shown that strict adherence to universal infection control practices among health care workers, as well as patients, reduced the incidence of HCV infections in hemodialysis patients. During 3 consecutive 18-month study periods from 1991 through 1995 the incidence declined from 1.4%, to 0.56% to 0% [15] . Although HCV-RNA assays were not used in that study, it strongly supports the concept that strict application of universal precautions is effective in reducing transmission of HCV among dialysis patients. As in our study, the seroprevalence in this study did not decline during the study period, because a substantial number of patients entered dialysis already infected with HCV.
Although most of the studies reported to date were too brief to draw definite conclusions, they indicate that an increased alertness of dialysis staff and the enforcement of hygienic measurements are important. One of our earlier studies showed that in only 3 of 27 investigated centers, dedicated dialysis equipment was used for HCV-infected patients [16] . It should be noted that the effects of strict implementation of universal precautions in dialysis patients are not restricted to HCV but have implications for all blood-borne pathogens. HCV can serve as a model for additional prospective studies to assess the impact of infection control and to monitor the effectiveness of the measures taken. In addition, regular training and auditing of health care workers, as well as patients, will be crucial.
In conclusion, the prevalence of HCV infections among dialysis patients in The Netherlands did not decrease after the introduction of blood and kidney donor screening programs, and nosocomial transmission within dialysis centers still occurs. In order to prevent future transmission of blood-borne pathogens, including HCV, among dialysis patients, we recommend an active approach, comprising enforcement of general hygienic measurements, training of patients and dialysis staff, and regular pathogen-specific testing.
